SCHEMBL6849487

SCHEMBL6849487

FC(F)(F)c1ccc(/C=N/NC(=S)NC2CC3C=CC2C3)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.66
XBP1 P17861 1/20 0.60
ALDH1A1 P00352 8/20 0.59
LMNA P02545 6/20 0.59
MAPT P10636 5/20 0.59
KDM4E B2RXH2 3/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
KMT2A Q03164 1/20 0.59
NPSR1 Q6W5P4 3/20 0.58
POLB P06746 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 3/20 0.47
HTT P42858 1/20 0.46
GALR3 O60755 1/20 0.45
PKM P14618 1/20 0.45
RECQL P46063 1/20 0.41
STS P08842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5182488 1.00 MAPK1 (0.66) MAPK1XBP1ALDH1A1LMNAMAPT
SCHEMBL6843098 0.87 GALR3 (0.62) MAPK1XBP1ALDH1A1LMNAMAPT
SCHEMBL6843099 0.87 GALR3 (0.62) MAPK1XBP1ALDH1A1LMNAMAPT
SCHEMBL6843084 0.86 MAPK1 (0.71) MAPK1ALDH1A1LMNAMAPTKDM4E
SCHEMBL5180221 0.86 MAPK1 (0.71) MAPK1ALDH1A1LMNAMAPTKDM4E
SCHEMBL5181505 0.85 MAPK1 (0.69) MAPK1ALDH1A1LMNAMAPTKDM4E
SCHEMBL5181004 0.85 MAPK1 (0.66) MAPK1ALDH1A1LMNAMAPTKDM4E
SCHEMBL6846979 0.85 MAPK1 (0.69) MAPK1ALDH1A1LMNAMAPTKDM4E
SCHEMBL6847925 0.85 MAPK1 (0.66) MAPK1ALDH1A1LMNAMAPTKDM4E
SCHEMBL5181732 0.84 ALDH1A1 (0.72) MAPK1ALDH1A1LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794400-B2 USE AS ANTICANCER AGENTS AND IN OTHER CONDITIONS INVOLVING ABNORMAL CELL PROLIFERATION SUCH AS RHEUMATOID ARTHRITIS CYTOVIA, INC. 2004-09-21 US disclosed
US-20030045581-A1 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof DISCOVER GROWTH FUND, LLC (VI) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045581-A1 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP3, CASP4 MAPK1 1962/4885XBP1 755/4885ALDH1A1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.